Healthcare >> CEO Interviews >> November 20, 2000

Karsten Henco – Evotec Biosystems Ag (566480.f)

DR KARSTEN HENCO, PhD, Chief Executive Officer, is a co-Founder of and Investor in EVOTEC BioSystems AG. Dr. Henco studied biochemistry at the University of Hannover, Hannover Medical School and Technische Hochschule Darmstadt. After receiving his PhD in 1979, he was a post- doctoral fellow in the laboratory of Prof Charles Weissmann at the University of Zurich where he cloned and characterised interferons and other important lymphokines. After three years at BASF AG in Ludwigshafen, where he was involved in the establishment of BASF's molecular biology and recombinant DNA technology facilities, Dr Henco co-founded QIAGEN GmbH and its subsidiary, QIAGEN, Inc in 1985. He served as Managing Partner of QIAGEN until 1993. Together with Dr Ulrich Aldag, QIAGEN's former CFO, Professors Manfred Eigen, Rudolf Rigler, Freimut Leidenberger and Heinrich Schulte, the Max-Planck Society and further scientists, Dr Henco founded EVOTEC BioSystems GmbH in December 1993. He has been Managing Director/CEO of the Company from its inception. EVOTEC have been listed on the Neuer Markt of the Frankfurt Stock Exchange since 10 November 1999. In 1997 Dr Henco received the Diesel award for his scientific and entrepreneurial work. Profile
TWST: Could you start us off with an introduction to EVOTEC?

Dr. Henco: EVOTEC OAI is a drug discovery company offering the full

range of biological and chemical drug discovery and development